4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies

San Francisco, CA US
October 5, 2024 to October 6, 2024

The 4th Binaytara Precision Oncology Summit is an annual 2-day CME-accredited national conference that offers an unparalleled opportunity for oncology professionals to delve into the latest advancements, innovations, and practices in precision oncology. The theme for this year's summit, "Current Standards and Emerging Therapies," highlights the conference's commitment to providing a comprehensive overview of the field, including in-depth discussions on the latest developments in precision oncology, alongside a thorough examination of established treatment protocols. Focus on actionable mutations ensures that the presented information translates directly into improved patient care.

The summit features didactics, panel discussions, interactive case studies, and scientific abstract presentations. 

This conference will augment healthcare providers' foundation of knowledge and clinical competence in several areas, including:

  • Integrating different platforms available for testing actionable molecular alterations to identify targeted therapy options.
  • Current and evolving paradigms in precision oncology approach for management of common malignancies.
  • Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

Organizing Committee 

Program Director:

Dr. Binay Shah - Binaytara Foundation

Conference Chair:

Dr. Charles M. Perou - UNC Lineberger Comprehensive Cancer Center

Conference Co-Chairs:

Dr. Mark Pegram - Stanford University

Dr. James Ford - Stanford University

Organizing Committee:

Dr. Siddhartha Yadav - Mayo Clinic

Dr. Jonathan Wesley Riess - UC Davis

Dr. Shivaani Kummar - Oregon Health & Science University

Dr. Diwakar Davar - UPMC Hillman Cancer Center

Dr. Christopher T. Chen - Stanford University

Dr. Shailender Bhatia - Fred Hutchinson Cancer Center / University of Washington

Dr. Pamela Munster - UCSF Helen Diller Family Comprehensive Cancer Center

Abstract Committee Chairs

Dr. Jonathan Wesley Riess - UC Davis

Dr. Marianne E. Dubard-Gault - Swedish Health Services

Abstract Committee

Dr. Mridula Krishnan - University of Nebraska Medical Center

Dr. Rajat Thawani - UChicago Medicine

Dr. Shipra Gandhi - Roswell Park Comprehensive Cancer Center

Dr. Matthew Schwede - Swedish Cancer Institute

Dr. Nicholas Mitsiades - UC Davis

Dr. Fatemeh Ardeshir-Larijani - Emory Winship Cancer Institute

Dr. Arya Mariam Roy - Roswell Park Comprehensive Cancer Center

Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
  • Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
  • Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.

HOTEL INFORMATION

A limited number of guestrooms are reserved at the Hyatt Regency San Francisco Downtown Soma for the participants of this meeting at a discounted rate of $199 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Thursday, September 12, 2024

Please use the link below to reserve your room for the discounted rate. The rate is good through Thursday, September 12, 2024.

https://www.hyatt.com/en-US/group-booking/SFORD/G-MBR4

Parking

Parking is available to overnight guests for $75 per day. 

Alternate parking options: Jessie Garage- $35 per day.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 11.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.75 Contact Hours.
Course opens: 
04/02/2024
Course expires: 
12/31/2024
Event starts: 
10/05/2024 - 8:00am PDT
Event ends: 
10/06/2024 - 3:30pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - OCTOBER 5th, 2024

All times listed in Pacific Daylight Time (PDT).

07:00 AM – 07:45 AM  Registration, Breakfast, & Exhibits

07:45 AM – 07:50 AM  Welcome

07:50 AM – 08:00 AM  Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart

08:00 AM – 09:00 AM  Session 1: Beyond NGS: Tools in Precision Oncology

Session Chair: Christopher T. Chen, MD

08:00 AM – 08:15 AM  WGS, WES, and Mutational Signatures for Identification of Complex Genomic Alterations Driving Cancer Development and Progression - Hanlee P. Ji, MD

08:15 AM – 08:30 AM  Potential Clinical Application(s) of Transcriptomics and Proteomics - Christopher T. Chen, MD

08:30 AM – 08:45 AM  CTCs and ctDNA to Aid Therapeutic Decisions and Surveillance - Pamela Munster, MD

08:45 AM – 09:00 AM  Discussion

09:00 AM – 10:00 AM  Session 2: DNA-Repair Deficiencies and Genomic Instability

Session Chair: James M. Ford, MD, FASCO

09:00 AM – 09:15 AM  Biomarkers of DNA-Repair Deficiencies, HRD, and Genomic Instability - Joshua Gruber, MD, PhD

09:15 AM – 09:30 AM  Translational Research Landscape for HR Deficient and Genomically Unstable Tumors - Shridar Ganesan, MD, PhD

09:30 AM – 09:45 AM  Next Generation of DNA-Repair Deficiency Targeted Treatments - Michael Cecchini, MD

09:45 AM – 10:00 AM  Discussion

 10:00 AM – 10:30 AM  Break & Exhibits

10:30 AM – 11:45 AM  Session 3: Cancer Immunotherapy

Session Chair: Diwakar Davar, MD

10:30 AM – 10:45 AM  Cancer Vaccines - Kiran Dhillon, PhD

10:45 AM – 11:00 AM  Innate Immune Signaling Pathways: How to Turn ‘Cold’ Tumors into ‘Hot’ Ones? - Diwakar Davar, MD

11:00 AM – 11:15 AM  Predicting Response/Resistance to Immune Checkpoint Inhibitors - Isaac Chan, MD, PhD

11:15 AM – 11:30 AM  Engineering Immune Cells to Treat Cancer (CAR-Ts and Beyond) - Jason Lohmueller, PhD

11:30 AM – 11:45 AM  Discussion

11:45 AM – 01:00 PM  Lunch & Exhibits

12:00 PM – 12:45 PM: Product Theater Sponsored by Merck in Salon 1

Topic: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Speaker: Jacek Pinski, MD

* This is a Non-CME activity *

01:00 PM – 01:45 PM  Session 4: Keynote

01:00 PM – 01:30 PM  Keynote Lecture - Glen N. Barber, PhD

01:30 PM – 01:45 PM  Discussion

01:45 PM – 02:45 PM  Session 5: RAS/RAF/MAPK and PI3 Kinase/AKT/mTOR Signaling

Session Chair: Shailender Bhatia, MD

01:45 PM – 02:00 PM  Therapeutic Opportunities Leveraging Aberrant RAS/RAF/MAPK Signaling - Ken Westover, MD, PhD

02:00 PM – 02:15 PM  Therapeutic Opportunities Leveraging Aberrant PI3 Kinase/AKT/mTOR Signaling - Neil M. Iyengar, MD

02:15 PM – 02:30 PM  Resistance Mechanisms and Challenges to Targeting RAS/RAF/MAPK and PI3 Kinase/AKT/mTOR Pathways - Roger S. Lo, MD, PhD

02:30 PM – 02:45 PM  Discussion

02:45 PM – 03:45 PM  Session 6: Hormone Receptor Signaling

Session Chair: Matthew Ellis, MB, BChir, PhD, FRCP

02:45 PM – 03:00 PM  Advances in Estrogen Receptor Signaling and Biology - Matthew Ellis, MB, BChir, PhD, FRCP

03:00 PM – 03:15 PM  Therapeutic Options for ESR1-Mutant Breast Cancers - Kelly E. McCann, MD, PhD

03:15 PM – 03:30 PM  Treatment Strategies Targeting the Androgen Receptor - Evan Y. Yu, MD

03:30 PM – 03:45 PM  Discussion

03:45 PM – 04:00 PM  Follicular Dendritic Cell Sarcoma, the SAINT Regimen and DeltaRex-G, a CCNG1 Inhibitor - Sant P. Chawla, MD

04:00 PM – 04:45 PM  Session 7: Oral Abstracts & Networking

Session Chairs: Jonathan Wesley Riess, MD, MS and Marianne E. Dubard-Gault, MD, MS

Durable Responses to Immune Checkpoint Inhibitor (ICI)-Based Regimens for Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Stratified by IMDC Risk Groups: A Pooled Analysis of Four Randomized Phase 3 Trials - Albert Jang, MD

Assessment of Cell-Free DNA (cfDNA) as a Biomarker in Upper Gastrointestinal (GI) Tract Malignancies: A Longitudinal Observational Cohort Study - Anura Kantak, MD

Impact of Alterations in Tumor Suppressor Genes (TSG-alt) on Survival Outcomes in Patients (pts) with De Novo Metastatic Hormone-Sensitive Prostate Cancer (dn-mHSPC) Receiving Androgen Deprivation Therapy (ADT) with Androgen Receptor Pathway Inhibition (ARPI) or Docetaxel - Zeynep Irem Ozay, MD

* This is a Non-CME activity *

 

DAY 2 - OCTOBER 6th, 2024

07:00 AM – 08:15 AM  Session 8: Poster Abstracts & Breakfast

Session Chairs: Jonathan Wesley Riess, MD, MS and Marianne E. Dubard-Gault, MD, MS

* This is a Non-CME activity *

08:15 AM – 09:30 AM  Session 9: Targeting Receptor Tyrosine Kinases

Session Chair: Jonathan Wesley Riess, MD, MS

08:15 AM – 08:30 AM  Biology of Receptor Tyrosine Kinases as Drivers of Cancer Pathogenesis - Trever G. Bivona, MD, PhD

08:30 AM – 08:45 AM  A Primer on Tyrosine Kinase Inhibitors and Implications for Management of EGFR, ALK, ROS1, MET and RET Altered Tumors - Christina S. Baik, MD, MPH

08:45 AM – 09:00 AM  HER2 Signaling in Breast and Other Cancers, and Implications for Treatment - Mark Pegram, MD

09:00 AM – 09:15 AM  Overcoming Challenges in Targeting Receptor Tyrosine Kinases and Resistance Mechanisms - Xiuning Le, MD, PhD

09:15 AM – 09:30 AM  Discussion

09:30 AM – 10:50 AM  Session 10: Molecular Tumor Board

Session Chair: Siddhartha Yadav, MBBS, MD

09:30 AM – 09:50 AM  Classical EGFR Mutation Positive Lung Cancer; Management over Multiple Lines of Therapy - Deepti Behl, MD

09:50 AM – 10:10 AM  ALK-Positive Non-Small Cell Lung Cancer - Kim-Son Nguyen, MD, MPA

10:10 AM – 10:30 AM  BRCA2 and Esophageal Cancer - Marianne E. Dubard-Gault, MD, MS

10:30 AM – 10:50 AM  Discussion

10:50 AM – 11:00 AM  Break & Exhibits

11:00 AM – 12:00 PM  Session 11: Cancer Interception and Prevention

Session Chair: Marianne E. Dubard-Gault, MD, MS

11:00 AM – 11:15 AM  Multi-Cancer Early Detection Tests – Clinical Utility and Pitfalls - Margaret Tempero, MD

11:15 AM – 11:30 AM  Personalized Vaccines for Primary or Secondary Cancer Prevention - Keith L. Knutson, PhD

11:30 AM – 11:45 AM  Precision in Cancer Risk Prediction Incorporating Genetic, Hormonal, and Environmental Risk Factors: Implications for Cancer Prevention - Fergus J. Couch, PhD

11:45 AM – 12:00 PM  Discussion

12:00 PM – 01:00 PM  Lunch & Exhibits

01:00 PM – 02:00 PM  Session 12: Precision Oncology Drug Development (Part 1)

Session Chair: Shivaani Kummar, MD, FACP

01:00 PM – 01:20 PM  Identifying Predictive Markers of Response and Resistance in Cancer Therapeutics - Shivaani Kummar, MD, FACP

01:20 PM – 01:35 PM  Developing Targeted Therapies for Children, Adolescents and Young Adults with Rare Tumors - Brigitte C. Widemann, MD

01:35 PM – 01:50 PM  How to Design Precision Clinical Trials for the Rare Targets - Ying Lu, PhD

01:50 PM – 02:00 PM  Discussion

02:00 PM – 03:15 PM  Session 13: Precision Oncology Drug Development (Part 2)

Session Chair: Pamela Munster, MD

02:00 PM – 02:15 PM  Antibody-Drug Conjugates: Opportunities and Challenges - Arlene O. Siefker-Radtke, MD

02:15 PM – 02:30 PM  Cellular Therapy: Where Do We Stand Now? - Krishna Komanduri, MD

02:30 PM – 02:45 PM  Bispecific Antibodies: Opportunities and Challenges - Omid Hamid, MD

02:45 PM – 03:00 PM  Quantitative Medicine for Breast Cancer Patients - Charles M. Perou, PhD

03:00 PM – 03:15 PM  Discussion

03:15 PM – 03:30 PM  Closing Remarks

Hyatt Regency San Francisco Downtown Soma
50 3rd St
San Francisco, CA 94103
United States

HOTEL INFORMATION

A limited number of guestrooms are reserved at the Hyatt Regency San Francisco Downtown Soma for the participants of this meeting at a discounted rate of $199 per night. The room rate does not include any additional fees or applicable taxes.

CUTOFF - Thursday, September 12, 2024

Please use the link below to reserve your room for the discounted rate. The rate is good through Thursday, September 12, 2024.

https://www.hyatt.com/en-US/group-booking/SFORD/G-MBR4

Parking

Parking is available to overnight guests for $75 per day. 

Alternate parking options: Jessie Garage- $35 per day.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Charles Perou

has a financial relationship (Patent) with Bioclassifier;.
has a financial relationship (Stock) with Reveal Genomics;.
has a financial relationship (Stock) with Bioclassifier;.
Session Chair(s)

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.

Christopher Chen

has a financial relationship (Grant Or Contract) with Mersana Therapeutics;.
has a financial relationship (Grant Or Contract) with ADC Therapeutics;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Professional Services) with Boxer Capital;.
has a financial relationship (Grant Or Contract) with Oric Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Merus;.
has a financial relationship (Professional Services) with Guidepoint Global Advisors;.
has a financial relationship (Grant Or Contract) with Kinnate Biopharma;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with Rain Oncology;.

Diwakar Davar, MD

has a financial relationship (Grant Or Contract) with Immunocore;.
has a financial relationship (Grant Or Contract) with Cellsight Technologies;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Arcus;.
has a financial relationship (Grant Or Contract) with Regeneron Pharmaceuticals Inc.;.
has a financial relationship (Grant Or Contract) with Merck;.

James Ford, MD, FASCO

has no relevant financial relationships to disclose at this time.

Shivaani Kummar

has a financial relationship (Grant Or Contract) with Moderna Inc;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with DOT Therapeutics-1 Inc.;.
has a financial relationship (Professional Services) with Springworks Therapeutics;.
has a financial relationship (Grant Or Contract) with Fog Pharmaceuticals;.
has a financial relationship (Professional Services) with HarbourBiomed;.
has a financial relationship (Professional Services) with BPGbio, Inc.;.
has a financial relationship (Professional Services) with GI Innovation Inc;.
has a financial relationship (Professional Services) with PathomIQ;.
has a financial relationship (Grant Or Contract) with Transcenta Therapeutics, Inc.;.
has a financial relationship (Grant Or Contract) with Gilead Sciences Inc.;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines Corp.;.
has a financial relationship (Professional Services) with Genome & Company;.
has a financial relationship (Professional Services) with Mundibiopharma;.
has a financial relationship (Professional Services) with Fortress Biotech, Inc;.
has a financial relationship (Professional Services) with Aadi Biosciences;.
has a financial relationship (Grant Or Contract) with Deciphera Pharmaceuticals LLC;.
has a financial relationship (Grant Or Contract) with Immunitas Therapeutics, Inc.;.
has a financial relationship (Grant Or Contract) with 23andMe Inc.;.
has a financial relationship (Grant Or Contract) with Astex Pharmaceuticals Inc.;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Oxford Biotherapeutics;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Genome Insight;.
has a financial relationship (Grant Or Contract) with SillaJen Inc.;.
has a financial relationship (Grant Or Contract) with AstraZeneca LP;.
has a financial relationship (Grant Or Contract) with Adanate, Inc.;.
has a financial relationship (Grant Or Contract) with PMV Pharmaceuticals, Inc.;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Grant Or Contract) with Nuvectis Pharma, Inc;.
has a financial relationship (Professional Services) with BPGbio Therapeutics;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with XYone Therapeutics;.
has a financial relationship (Grant Or Contract) with Incyte;.

Pamela Munster

has a financial relationship (Independent contractor) with Johnson and Johnson ;.
has a financial relationship (Grant Or Contract) with genetech;.
has a financial relationship (Grant Or Contract) with Seagen;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Revolution;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Clovis;.

Jonathan Riess, MD, MS

has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Biodesix;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Astrazeneca ;.
has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
Speaker/Topic Presenter(s)

Christina Baik, MD MPH

has no relevant financial relationships to disclose at this time.

glen barber, Dr. Glen Barber, PhD, FRS, is a professor in the Department of Surgery/Division of Oncology, Director of the Center for Innate Immunity and Inflammation and Associate Director of Entrepreneurship and Innovation with the James Comprehensive Cancer Center, 

has a financial relationship (Other) with stinginn;.

Trever Bivona, MD, PhD

has a financial relationship (Professional Services) with Astrazeneca;.
has a financial relationship (Professional Services) with Relay Therapeutics;.
has a financial relationship (Professional Services) with Revolution Medicines;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Abbvie;.

Michael Cecchini, MD

has a financial relationship (Financial Support) with Regeneron;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Financial Support) with Taiho;.
has a financial relationship (Financial Support) with LoxoLilly;.
has a financial relationship (Financial Support) with Arcus;.
has a financial relationship (Financial Support) with Seattle Genetics;.
has a financial relationship (Financial Support) with Agenus;.
has a financial relationship (Financial Support) with Beigene;.
has a financial relationship (Financial Support) with Incendia Therapeutics;.
has a financial relationship (Financial Support) with Daiichi Sankyo;.

Isaac Chan

has no relevant financial relationships to disclose at this time.

Fergus Couch, PhD

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with GRAIL;.

Kiran Dhillon, PhD

has no relevant financial relationships to disclose at this time.

Matthew ellis, MB., BChir., Ph.D., FRCP.

has a financial relationship (Patent) with Veracyte;.
has a financial relationship (Employment) with AstraZeneca;.

Shridar Ganesan, MD, PhD

has a financial relationship (Employment) with Merck;.
has a financial relationship (Independent contractor) with EMD Seranoi;.
has a financial relationship (Independent contractor) with KayoThera;.
has a financial relationship (Independent contractor) with Foghorn Rx;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Lunit;.

Joshua Gruber, MD, PhD

has a financial relationship (Independent contractor) with Sharma Therapeutics;.
has a financial relationship (Independent contractor) with Guidepoint;.
has a financial relationship (Grant Or Contract) with Hummingbird Bioscience;.
has a financial relationship (Employment) with Guardant Health;.
has a financial relationship (Independent contractor) with Hologic;.

Omid Hamid

has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Tempus;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Immunocore;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Stock) with Bactonix;.
has a financial relationship (Professional Services) with GigaGen;.
has a financial relationship (Professional Services) with Immunocore;.
has a financial relationship (Professional Services) with Iovance;.
has a financial relationship (Professional Services) with Moderna;.
has a financial relationship (Professional Services) with Obsidian;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Professional Services) with Alkermes;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bioatla;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Georgiamune;.
has a financial relationship (Professional Services) with Idera;.
has a financial relationship (Professional Services) with IO Biotech;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Zelluna;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Roche Genentech;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Instilbio;.
has a financial relationship (Professional Services) with KSQ;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Vial Health Tech;.
has a financial relationship (Professional Services) with Bactonix;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Eisai Biotech;.
has a financial relationship (Grant Or Contract) with Arcus;.
has a financial relationship (Professional Services) with Grit Bio;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with NGM Bio;.

Neil Iyengar

has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with SynDevRx;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with TerSera Therapeutics;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Daichii-Sankyo;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Menarini-Stemline;.
has a financial relationship (Independent contractor) with BD Life Sciences;.
has a financial relationship (Independent contractor) with Genentech/Roche;.

Hanlee Ji, MD

has a financial relationship (Grant Or Contract) with 10X Genomics;.
has a financial relationship (Travel) with Oxford Nanopore;.

Keith Knutson

has no relevant financial relationships to disclose at this time.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Optum Health;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.
has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.

Xiuning Le, MD PhD

has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Pinetree;.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Independent contractor) with Abion;.
has a financial relationship (Independent contractor) with Teligene;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Daiichi;.
has a financial relationship (Independent contractor) with SystImmune;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Blueprint;.
has a financial relationship (Stock Options) with Bloomhills;.

Roger Lo, MD, PhD

has no relevant financial relationships to disclose at this time.

Jason Lohmueller

has a financial relationship (Other Business Ownership) with Monarch Therapeutics;.
has a financial relationship (Professional Services) with NeoCell Technologies;.
has a financial relationship (Stock) with GenCART, Inc.;.
has a financial relationship (Stock Options) with NeoCell Technologies;.
has a financial relationship (Patent) with Coeptis Therapeutics;.
has a financial relationship (Grant Or Contract) with Coeptis Therapeutics;.
has a financial relationship (Patent) with Monarch Therapeutics;.
has a financial relationship (Professional Services) with UPMC Enterprises;.
has a financial relationship (Grant Or Contract) with GenCART Inc.;.

Ying Lu, PhD

has a financial relationship (Independent contractor) with DPC Clinical;.

Kelly McCann, MD, PhD

has a financial relationship (Travel) with Eli Lilly;.

Mark Pegram, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Gilead;.

Arlene Siefker-Radtke, MD

has a financial relationship (Grant Or Contract) with Basilea Pharmaceutica;.
has a financial relationship (Grant Or Contract) with Millennium;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Ideeya Biosciences ;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Taiho;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with G1 Therapeutics;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Nektar Therapeutics;.

Margaret Tempero

has a financial relationship (Professional Services) with Bio Ascend-B2ACT Therapeutics Genex;.
has a financial relationship (Professional Services) with Blueprint;.
has a financial relationship (Professional Services) with Debiopharm;.
has a financial relationship (Professional Services) with Mirati Therapeutics Inc.;.
has a financial relationship (Professional Services) with Global Bio Access Fund;.
has a financial relationship (Professional Services) with RenovoRx;.
has a financial relationship (Professional Services) with BioSapiens;.
has a financial relationship (Professional Services) with Exact Sciences;.
has a financial relationship (Professional Services) with IPSEN Biopharma, Inc.;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Biotech Research;.
has a financial relationship (Professional Services) with ElmediX;.
has a financial relationship (Professional Services) with Global Bio Access Fund;.
has a financial relationship (Professional Services) with Merus;.
has a financial relationship (Professional Services) with Geron Corporation;.
has a financial relationship (Professional Services) with Janssen Research and Development;.
has a financial relationship (Professional Services) with Astellas Pharma Global Development Inc.;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Geistlich Pharma;.
has a financial relationship (Professional Services) with ONCOLYTICS;.
has a financial relationship (Professional Services) with PEPTOMYC, S.L.;.
has a financial relationship (Professional Services) with Guardant Health;.

Ken Westover, Associate Professor of Biochemistry and Radiation Oncology

has a financial relationship (Stock Options) with Velorum Thearpeutics;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Stock Options) with Vibliome Pharma;.

Brigitte Widemann

has no relevant financial relationships to disclose at this time.

Evan Yu, Professor of Medicine, University of Washington

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with janssen;.

Sant Chawla, M.D., FRACP

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with NKMax;.
has a financial relationship (Professional Services) with Immune Design;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with NKMax;.
has a financial relationship (Stock) with Counterpoint Biomedica LLC;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Immune Design;.
has a financial relationship (Professional Services) with Sarcoma Alliance for Research through Collaboration (SARC);.
has a financial relationship (Professional Services) with Inhibrx;.
has a financial relationship (Professional Services) with Ignyta;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Sarcoma Alliance for Research through Collaboration (SARC);.
has a financial relationship (Professional Services) with Inhibrx;.
has a financial relationship (Stock) with Cellestia Biotech;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Ignyta;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with CytRx Corporation;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Stock) with AADi;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with CytRx Corporation;.
has a financial relationship (Professional Services) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with Advenchen Laboratories;.
has a financial relationship (Professional Services) with Threshhold Pharmaceuticals;.
has a financial relationship (Professional Services) with Thyme;.
has a financial relationship (Professional Services) with TRACON Pharma;.
has a financial relationship (Professional Services) with Advenchen Laboratories;.
has a financial relationship (Professional Services) with Thyme;.
has a financial relationship (Stock) with Immix BioPharma;.
has a financial relationship (Professional Services) with Threshhold Pharmaceuticals;.
has a financial relationship (Professional Services) with TRACON Pharma;.

Kim-Son Nguyen

has no relevant financial relationships to disclose at this time.

Ranjan Pathak, MBBS, MHS, FACP

has no relevant financial relationships to disclose at this time.
Planning committee(s)

Fatemeh Ardeshir Larijani

has no relevant financial relationships to disclose at this time.

Marianne Dubard-Gault, MD, MS

has no relevant financial relationships to disclose at this time.

Shipra Gandhi, MD, MS

has a financial relationship (Other) with Astrazeneca;.
has a financial relationship (Other) with Biotheranostics ;.

Mridula Krishnan

has no relevant financial relationships to disclose at this time.

Nicholas Mitsiades, Professor, Department of Internal Medicine, Division of Hematology and Oncology / Chief Translational Office and Associate Director for Translational Research, UC Davis Comprehensive Cancer Center

has no relevant financial relationships to disclose at this time.

Mark Pegram, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Gilead;.

Arya Mariam Roy, MD

has no relevant financial relationships to disclose at this time.

Matthew Schwede, MD, MS

has no relevant financial relationships to disclose at this time.

Rajat Thawani, MD

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
has a financial relationship (Other) with Repare Therapeutics;.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education Grants from:

  • Exact Sciences
  • Pfizer
  • Puma Biotechnology
  • Novartis

Available Credit

  • 11.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.75 Contact Hours.
NameExhibit typeRequester  Name2nd Rep  Name
Daiichi SankyoGeneral ExhibitMonica FerroneAndrew Von Kleeck
Daiichi Sankyo - 2nd tableGeneral ExhibitMark HankeWhitney Williams
MerckLunch PT day 1Andy PetersonLeah Brunette
Menarini StemlineGeneral ExhibitBert YeeBrenda Johnson
ImmunocoreGeneral ExhibitPatrick Short 
GSKGeneral ExhibitDarin ParvinRonald Palmer
IncyteGeneral ExhibitCarole YatesJohn Lee
Foundation MedicineGeneral ExhibitBrie Jennings 
IpsenGeneral ExhibitErin McCueLuis Zuniga
PfizerGeneral ExhibitDeb LeeDonna Corsell
MerckGeneral ExhibitRyan Collins 
JNJGeneral ExhibitJane Lafonta 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.